clinical trial

[Ageless Biotech, Inc. (PR Newswire, Inc.)] Ageless Biotech, Inc. acquired a US FDA Investigational New Drug Application for the treatment of osteoarthritis of the knee, using minimally manipulated adipose derived stem cells without enzymes or other chemicals through a proprietary process of a well-known method referred to as stromal vascular fraction.

[4D pharma plc] 4D pharma plc announced that the US FDA has cleared investigational new drug (IND) applications for two live biotherapeutics, MRx0005 and MRx0029, for the treatment of Parkinson’s disease.

[Acticor Biotech] Acticor Biotech announced positive results from its ACTIMIS Phase Ib/IIa clinical trial using glenzocimab as an add-on to standard of care in patients with AIS.

[Ayala Pharmaceuticals, Inc.] Ayala Pharmaceuticals, Inc. announced that it has completed patient enrollment in Part A of the Phase II/III RINGSIDE clinical trial evaluating AL102 in desmoid tumors.

[MyMD Pharmaceuticals, Inc. (BusinessWire, Inc.)] MyMD Pharmaceuticals, Inc. announced that the first patient has been enrolled in the company’s Phase II clinical trial of lead candidate MYMD-1, an oral immune regulator drug, as a therapy for delaying aging and expanding healthy lifespan.

[Scientific Reports] Scientists conducted a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxyurea in transfusion-dependent β-thalassaemia.